“A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab ‘Bio-similar’ in a previously therapy naive adult”, Indian J Case Reports, vol. 8, no. 3, pp. 58–61, Mar. 2022, doi: 10.32677/ijcr.v8i3.3317.